FSD Pharma, a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announced the completion of dosing the first cohort of patients in the company’s Phase I clinical trial of Lucid-21-302 (Lucid-MS). The clinical trial (ClinicalTrials.gov Identifier: NCT05821387), being conducted by FSD Pharma through the Company’s wholly owned subsidiary Lucid Psycheceuticals, is a first-in-human study evaluating Lucid-MS, a small molecule inhibitor of hypercitrullination, as a novel drug candidate for the treatment of Multiple Sclerosis (MS).

“Our clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort,” said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals. “The safety review committee has recommended to move forward with the next cohort dosing, which we are thrilled to say is expected to commence in the next few days.”

The clinical trial is a randomized, double-blind, placebo controlled, single ascending dose and multiple ascending dose study with the primary outcomes evaluating the safety, tolerability, and pharmacokinetics of Lucid-MS in healthy volunteers under fed and fasted conditions.